Gene expression programs are markedly altered in breast cancer. These alterations are often associated to exceeding levels of key oncogenes, such as MYC, and the deregulation of factors important for the control of RNA modifications. We hypothesised that the aberrant role of MYC depends on specific alterations of the RNA metabolism controlled by changes in their modifications. These studies could reveal novel downstream effectors to target the so far undruggable MYC oncogene, and could reveal novel therapeutical strategies for the treatment of breast cancer.